Xin Lang Cai Jing·2025-07-04 05:41Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has shown a strong increase of 1.56% as of July 4, 2025, with notable gains from constituent stocks such as Zhenhua Cell (688520) up 14.55%, Rongchang Bio (688331) up 12.37%, and Shanghai Yizhong (688091) up 8.67% [1] - The Sci-Tech Biopharmaceutical ETF (588250) rose by 1.62%, with a latest price of 1.13 yuan, and has accumulated a 2.88% increase over the past week as of July 3, 2025 [1] - Baili Tianheng announced that its self-developed first-in-class EGFRXHER3 dual antibody ADC (iza-bren) has reached its primary endpoint in a Phase III clinical trial for nasopharyngeal carcinoma, marking it as the first dual antibody ADC to enter Phase III globally [1] Group 2 - Changchun High-tech's IL-1β monoclonal antibody (Fuxin Qibai) has been approved for the acute gout market, which is projected to be worth billions, and is noted for its rapid onset and low recurrence rate compared to existing NSAIDs and steroid therapies [2] - The approval of this product is expected to enhance Changchun High-tech's product portfolio in the adult autoimmune sector and strengthen its competitive position in the pharmaceutical market [2] - The policy to open public data resources in the medical insurance sector for innovative drug development is anticipated to significantly improve the efficiency of innovative drug research and development [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) include Yuying Medical (688271), BeiGene (688235), and Huatai Medical (688617), with these ten stocks accounting for a total of 50.3% of the index [3]